Loading clinical trials...
Loading clinical trials...
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Conditions
Interventions
tisotumab vedotin
Locations
53
United States
University of Alabama
Birmingham, Alabama, United States
Arizona Oncology Associate - Biltmore Cancer Center
Phoenix, Arizona, United States
UCLA Dept. of OBGYN
Los Angeles, California, United States
Southern Baptist Hospital of Florida, Inc
Jacksonville, Florida, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
University of Gynecologic Oncology
Atlanta, Georgia, United States
Start Date
June 12, 2018
Primary Completion Date
February 6, 2020
Completion Date
August 2, 2022
Last Updated
July 25, 2023
NCT06157151
NCT06952660
NCT04895709
NCT05108298
NCT05952141
NCT07276360
Lead Sponsor
Seagen Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions